Incyte Genomics Inc - INCY STOCK NEWS

Incyte has appointed Dr. Otis Brawley to its Board of Directors, effective September 27, 2021. Dr. Brawley brings extensive clinical experience, having served at Johns Hopkins University and the American Cancer Society. His appointment is expected to enhance the board's capabilities in advancing scientific discovery and developing innovative medicines. CEO Hervé Hoppenot expressed confidence in Dr. Brawley's contributions to the company's future success.

Syndax Pharmaceuticals and Incyte announced a global collaboration to develop axatilimab, an anti-CSF-1R monoclonal antibody, focusing on chronic graft-versus-host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). Syndax will receive $117 million upfront and $35 million in equity investment, along with potential milestone payments of up to $450 million. The companies will share profits in the U.S. 50:50, with Syndax receiving double-digit royalties internationally. Ongoing trials for axatilimab aim to provide innovative treatments for patients with severe conditions, with topline data expected in 2023.

Incyte announced that the FDA approved Jakafi (ruxolitinib) for treating chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in patients aged 12 and older. This marks Jakafi's fourth FDA-approved indication, following its approval for steroid-refractory acute GVHD in 2019. The approval is based on the REACH3 trial, which showed a 49.7% overall response rate for Jakafi versus 25.6% for best available therapy at Week 24. Chronic GVHD affects over 14,000 patients in the U.S.

Incyte announced FDA approval for Opzelura (ruxolitinib) cream, the first topical JAK inhibitor for treating mild to moderate atopic dermatitis (AD) in patients aged 12 and older. Approval was based on the TRuE-AD clinical trial, where nearly 54% of patients achieved significant treatment success at week 8. Common side effects include nasopharyngitis and diarrhea. Over 21 million Americans suffer from AD, highlighting the market potential of Opzelura. The company plans to support patients through the IncyteCARES program and recently scheduled an investor conference call for September 22, 2021.

Nimble Therapeutics has expanded its strategic research collaboration with Incyte to discover additional novel peptide therapies. CEO Jigar Patel highlighted this collaboration as a validation of Nimble's capabilities in peptide therapeutics. Under the agreement, Nimble will receive an upfront payment and reimbursement for certain research costs and may be eligible for milestone payments and royalties. Incyte retains exclusive rights to develop and commercialize any peptides discovered during the collaboration and has options for further expansion.

Incyte announced that data from the Phase 3 TRuE-V program of ruxolitinib cream for treating vitiligo will be presented during a late-breaking oral presentation at the EADV 30th Anniversary Congress from September 29 to October 2, 2021. Both TRuE-V1 and TRuE-V2 studies met primary and key secondary endpoints. The highlights include safety and efficacy results for ruxolitinib cream, which shows potential as an effective treatment for patients with vitiligo and atopic dermatitis. This development underscores Incyte's commitment to addressing unmet medical needs in dermatology.

Incyte and MorphoSys AG have received conditional marketing authorization from the European Commission for Minjuvi (tafasitamab) in combination with lenalidomide. This approval is intended for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. The decision is supported by positive data from the L-MIND study, showing an overall response rate of 56.8%. Approximately 16,000 patients are diagnosed annually with this condition in the EU.

Incyte (Nasdaq:INCY) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 11:45 a.m. ET. The presentation will be available via a live webcast, and a replay will be accessible for 90 days afterward.

Incyte, a biopharmaceutical company based in Wilmington, Delaware, focuses on addressing significant unmet medical needs through innovative therapeutics. For further details, visit Incyte.com.

Incyte and InnoCare have announced a collaboration for the development and commercialization of tafasitamab in Greater China. Incyte will receive an upfront payment of US$35 million and has the potential to earn up to US$82.5 million in milestones and royalties. InnoCare will develop and commercialize tafasitamab in hematology and oncology across mainland China, Hong Kong, Macau, and Taiwan. This partnership aims to expedite access to this FDA-approved treatment for eligible patients, leveraging InnoCare's local expertise.